A detailed history of Core Alternative Capital transactions in Incyte Corp stock. As of the latest transaction made, Core Alternative Capital holds 21 shares of INCY stock, worth $1,506. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21
Previous 21 -0.0%
Holding current value
$1,506
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$56.55 - $66.59 $8,199 - $9,655
-145 Reduced 87.35%
21 $1,000
Q4 2023

Feb 14, 2024

SELL
$52.16 - $64.19 $521 - $641
-10 Reduced 5.68%
166 $10,000
Q2 2023

Jul 27, 2023

BUY
$60.95 - $75.51 $670 - $830
11 Added 6.67%
176 $10,000
Q1 2023

Apr 18, 2023

BUY
$70.23 - $86.01 $1,755 - $2,150
25 Added 17.86%
165 $11,000
Q2 2022

Aug 01, 2022

BUY
$66.18 - $83.18 $3,904 - $4,907
59 Added 72.84%
140 $11,000
Q1 2022

May 10, 2022

BUY
$66.02 - $79.71 $5,347 - $6,456
81 New
81 $6,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Core Alternative Capital Portfolio

Follow Core Alternative Capital and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Core Alternative Capital, based on Form 13F filings with the SEC.

News

Stay updated on Core Alternative Capital with notifications on news.